Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
A UHN study has revealed a new therapeutic approach that could help to treat glioblastoma, the most common and most aggressive form of brain cancer in adults.
In 2017, glioblastoma claimed the life of Gord Downie, the frontman of iconic Canadian rock band, The Tragically Hip.
Glioblastoma is a deadly cancer diagnosed in approximately 1,000 Canadians every year. Less than five per cent of these individuals survive more than five years.
The rates of survival are dismal because most of these brain tumours do not respond to current treatments. New and more effective treatments are therefore urgently needed for this disease.
In the study,
Dr. Valerie Wallace, a Senior Scientist at the Krembil Research Institute, and her trainee, Dr. Ahmed El-Sehemy, discovered that the protein Norrin plays an important role – albeit a complicated one – in the growth and proliferation of glioblastoma tumours.
"Norrin has been implicated in blood vessel formation in the brain, eye and inner ear, and the regulation of brain cell behaviour," Dr. Wallace says. "Our findings indicate that Norrin is present in a wide range of brain tumours and that higher levels of the protein are linked to better patient survival."
Glioblastoma tumours contain a small number of specialized cells known as cancer stem cells, which can give rise to new tumour cells. These stem cells are widely believed to be responsible for the cancer's resistance to treatment and its recurrence. Accordingly, targeting these cells could be the key to treating glioblastoma.
The researchers found that Norrin affects the growth and proliferation of a tumour's cancer stem cells.
In stem cells with high levels of the ASCL1 protein, Norrin promoted cell growth, whereas in cells with low ASCL1 levels, Norrin inhibited growth. Although ASCL1's role in brain cancer is not entirely clear yet, the protein is known to be involved in the generation of brain cells during development.
"Our study reveals an unanticipated role of Norrin in brain cancer progression," Dr. Wallace says. "Norrin could be a potential therapeutic target for glioblastoma tumours and may inform the design of patient-specific treatments."
This work was supported by the Cancer Research Society, the Canadian Institutes of Health Research and the Toronto General & Western Hospital Foundation. Dr. Wallace holds a Tier 1 Canada Research Chair in Retina Regeneration.